Skip to main content

Christina Pellegrini

Christina Pellegrini
Cannabis Industry Reporter
Toronto

Christina Pellegrini is a business reporter at The Globe and Mail.

She covers the cannabis industry and has been doing so since August, 2017. She writes about companies, deal-making and regulation. Before that, she covered capital markets and telecom. She holds a Master of Journalism from Ryerson University and a Bachelor of Business Administration from the Schulich School of Business at York University.

Latest articles
Coke, Aurora and CBD: The reality of mixing beverages with pot Subscriber content
Aurora says there isn’t a deal with Coca-Cola on marijuana-based drinks
Cannabis grower CannTrust says no guarantee of U.S. listing; weighing options Subscriber content
Canadian military directed that they can use marijuana 8 hours before work Subscriber content
Aphria stock surges as it sells the last of its U.S. assets Subscriber content
Short-seller Citron takes aim at Tilray Inc. less than a week after sounding alarm on Cronos Subscriber content
Beverage makers explore entries to Canadian cannabis sector
Alberta and Ontario brace for the age of legal pot
Drugstores, in-store pharmacies push for right to sell recreational cannabis Subscriber content
Marijuana stocks plummet in wake of Ontario’s private-sector sales delay Subscriber content
Ontario delays debut of private-sector cannabis Subscriber content
Green rush: The race to sell cannabis in Canada Subscriber content
Molson Coors Canada enters cannabis sector with Hydropothecary partnership Subscriber content
Manulife, Shoppers partner in medical cannabis program
Uncertainty reigns as Ontario moves to private pot retail Subscriber content
Pilsner and pot: Steam Whistle eyed for takeover Subscriber content
Ontario government will turn to private retailers to sell marijuana Subscriber content
Tilray Inc. becomes first cannabis grower to complete an IPO in the U.S. Subscriber content
Tilray shares pop in U.S. trading debut after raising US$153-million in IPO
Aurora, MedReleaf shareholders clear path toward Canada’s largest cannabis deal Subscriber content